DaVita Labs appoints vp and general manager
Chronic kidney disease laboratory hires Leslie Mirani
Mirani brings to DaVita Labs more than 25 years’ experience in commercial sales and marketing – primarily renal-focused – in the pharmaceutical industry. She previously worked for Human Genome Sciences as an immunology sales director and as vice president for Amgen’s nephrology business unit for 18 years.
DaVita Labs has 86,700ft2 dedicated to its clinical diagnostic laboratories between its two locations in Fort Lauderdale and DeLand, Florida, US.
You may also like
Research & Development
![Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal]()
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal
Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
![FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance]()
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance
The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
![Early phase analytical strategy for biosimilars in a shifting regulatory landscape]()
Early phase analytical strategy for biosimilars in a shifting regulatory landscape
As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
